-
Tytuł:
-
Nanomedicine for glioblastoma: Progress and future prospects.
-
Autorzy:
-
Khan I; Department of Molecular Biology, Beykoz Institute of Life Sciences and Biotechnology, Bezmialem Vakif University, Yalıköy St., Beykoz, Istanbul, Turkey.
Baig MH; Department of Family Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Gangnam-gu, Seoul 120-752, Republic of Korea.
Mahfooz S; Department of Molecular Biology, Beykoz Institute of Life Sciences and Biotechnology, Bezmialem Vakif University, Yalıköy St., Beykoz, Istanbul, Turkey.
Imran MA; Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Gangnam-gu, Seoul 120-752, Republic of Korea.
Khan MI; Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Gangnam-gu, Seoul 120-752, Republic of Korea.
Dong JJ; Department of Family Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Gangnam-gu, Seoul 120-752, Republic of Korea.
Cho JY; Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Gangnam-gu, Seoul 120-752, Republic of Korea. Electronic address: .
Hatiboglu MA; Department of Molecular Biology, Beykoz Institute of Life Sciences and Biotechnology, Bezmialem Vakif University, Yalıköy St., Beykoz, Istanbul, Turkey; Department of Neurosurgery, Bezmialem Vakif University Medical School, Vatan Street, Fatih, Istanbul, Turkey. Electronic address: .
-
Źródło:
-
Seminars in cancer biology [Semin Cancer Biol] 2022 Nov; Vol. 86 (Pt 2), pp. 172-186. Date of Electronic Publication: 2022 Jun 26.
-
Typ publikacji:
-
Journal Article; Review; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: London : Academic Press
Original Publication: Philadelphia, PA, USA : Saunders Scientific Publications, W.B. Saunders Co., c1990-
-
MeSH Terms:
-
Glioblastoma*/therapy
Glioblastoma*/drug therapy
Brain Neoplasms*/diagnosis
Brain Neoplasms*/drug therapy
Humans ; Nanomedicine ; Temozolomide/therapeutic use ; Blood-Brain Barrier/pathology
-
Contributed Indexing:
-
Keywords: Blood brain barrier; Exosomes; Glioblastoma; Liposomes; Nanoparticle
-
Substance Nomenclature:
-
YF1K15M17Y (Temozolomide)
-
Entry Date(s):
-
Date Created: 20220627 Date Completed: 20221116 Latest Revision: 20221118
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.semcancer.2022.06.007
-
PMID:
-
35760272
-
Glioblastoma is the most aggressive form of brain tumor, accounting for the highest mortality and morbidity rates. Current treatment for patients with glioblastoma includes maximal safe tumor resection followed by radiation therapy with concomitant temozolomide (TMZ) chemotherapy. The addition of TMZ to the conformal radiation therapy has improved the median survival time only from 12 months to 16 months in patients with glioblastoma. Despite these aggressive treatment strategies, patients' prognosis remains poor. This therapeutic failure is primarily attributed to the blood-brain barrier (BBB) that restricts the transport of TMZ from reaching the tumor site. In recent years, nanomedicine has gained considerable attention among researchers and shown promising developments in clinical applications, including the diagnosis, prognosis, and treatment of glioblastoma tumors. This review sheds light on the morphological and physiological complexity of the BBB. It also explains the development of nanomedicine strategies to enhance the permeability of drug molecules across the BBB.
(Copyright © 2022. Published by Elsevier Ltd.)